Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [111In]-FPI-2107
FPI-2107 · 1 trial · 1 indication
Safety and tolerability will be evaluated by frequency, duration, and severity of AEs, and changes in clinical, laboratory, and ECG parameters compared to baseline
Residence time of the segmented source organs
| Arm | Type | Description |
|---|---|---|
| [111In]-FPI-2107 and FPI-2053 | EXPERIMENTAL | 2 study interventions both based on the same EGFR and c-MET bispecific antibody |
| Name | Type | Description |
|---|---|---|
| [111In]-FPI-2107 | DRUG | radioimmuno-SPECT agent |
| FPI-2053 | DRUG | unconjugated/unlabelled bispecific antibody \[cold\] |
Inclusion Criteria: * Histologically or cytologically confirmed EGFR mutation positive NSCLC. * Without any ongoing anti-cancer therapy or with stable ongoing anti-cancer therapy. * At least one lesion that is present on 18F-FDG PET/CT scan during screening. * ECOG performance status of 0 or 1. * A...
FPI-2107 is an investigational small molecule being developed for use in EGFR mutation-positive non-small cell lung cancer (NSCLC). It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
FPI-2107 is being studied in patients with EGFR mutation-positive NSCLC, indicating it is designed to interact with the EGFR pathway. The specific molecular target of FPI-2107 has not been disclosed in available information.
FPI-2107 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN.
FPI-2107 is in Phase 1 clinical development. It is an investigational drug and has not received approval from regulatory authorities for any use.
FPI-2107 is being evaluated in a Phase 1 clinical trial with the identifier NCT07500987. This study is recruiting participants with EGFR mutation-positive NSCLC in China and has an enrollment target of 12 patients.
Yes, FPI-2107 is also known as [111In]-FPI-2107. The alternative name reflects the radiolabeled form of the compound, which is used in the clinical trial setting.